Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target hoisted by equities research analysts at HC Wainwright from $115.00 to $120.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 36.91% from the stock’s previous close.

Several other research firms have also commented on ARWR. Chardan Capital upped their price target on shares of Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd. Royal Bank Of Canada boosted their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Stifel Nicolaus assumed coverage on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They issued a “buy” rating and a $98.00 price target on the stock. Leerink Partners lifted their target price on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a report on Wednesday, June 17th. Finally, Weiss Ratings cut shares of Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a report on Wednesday, May 20th. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $97.33.

Arrowhead Pharmaceuticals Stock Up 2.1%

ARWR stock opened at $87.65 on Thursday. The firm has a market cap of $12.35 billion, a price-to-earnings ratio of -38.96 and a beta of 1.27. Arrowhead Pharmaceuticals has a 1-year low of $15.01 and a 1-year high of $95.49. The firm has a fifty day moving average price of $79.97 and a two-hundred day moving average price of $71.43. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 6.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The company had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. During the same quarter in the previous year, the firm earned ($1.26) earnings per share. The business’s revenue was up 171.0% on a year-over-year basis. Research analysts predict that Arrowhead Pharmaceuticals will post -3.4 EPS for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director Hongbo Lu sold 2,970 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total value of $228,333.60. Following the completion of the sale, the director directly owned 52,012 shares of the company’s stock, valued at $3,998,682.56. This represents a 5.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc grew its holdings in shares of Arrowhead Pharmaceuticals by 285.1% during the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC boosted its position in Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 154 shares during the last quarter. Tsfg LLC purchased a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at about $25,000. Optiver Holding B.V. grew its stake in Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares in the last quarter. Finally, First Horizon Corp acquired a new position in Arrowhead Pharmaceuticals in the 4th quarter worth about $32,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.